Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Tuesday, October 12, 2010 - 12:01
in Health & Medicine
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.